Search Results - Graddis, Tom

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response

    519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response by Zuck, Meghan, Green, Kevin, Pisarenko, Tatyana, Dinh, Huyen, Bouchlaka, Myriam, Zapata, Francisco, Hay, Elsa L, Naika, Gajendra, Heit, Jacob, Fox, Ray, Whitman, Darbie, Graddis, Tom, Puri, Kamal D, Probst, Peter

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses

    494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses by Bouchlaka, Myriam N, Zuck, Meghan, Dinh, Huyen, Green, Kevin, Pisarenko, Tatyana, Zapata, Francisco, Hay, Elsa L, Naika, Gajendra, Heit, Jacob, Fox, Ray, Whitman, Darbie, Graddis, Tom, Puri, Kamal D, Probst, Peter

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    262 Preclinical characterization of humanized anti-siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

    262 Preclinical characterization of humanized anti-siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression by Dinh, Huyen, Lam, Sam, Wall, Valerie, Zapata, Francisco, Whitman, Darbie, Chandrasekaran, Ramya, Loh, Lauren, Loh, Texia, Graddis, Tom, Probst, Peter, Bouchlaka, Myriam

    Request full text
    Article
    Save to List
    Saved in:
  4. 4
    271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

    271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages by Probst, Peter, Simmons, Randi, Dinh, Huyen, Zuck, Meghan, Wall, Valerie, Bouchlaka, Myriam, Lam, Sam, Fox, Ray, Whitman, Darbie, Graddis, Tom, Puri, Kamal

    Request full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    276 Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression

    276 Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression by Zuck, Meghan, Dinh, Huyen, Wall, Valerie, Lam, Sam, Chandrasekaran, Ramya, Zapata, Francisco, Loh, Texia, Loh, Lauren, Bouchlaka, Myriam, Graddis, Tom, Puri, Kamal, Probst, Peter

    Request full text
    Article
    Save to List
    Saved in:
  6. 6
    39 Interrogating elite responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer

    39 Interrogating elite responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer by Chandrasekaran, Ramya, Whitman, Darbie, Fox, Ray, Graddis, Tom, Puri, Kamal

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Abstract 1719: OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages

    Abstract 1719: OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages by Probst, Peter, Simmons, Randi, Wall, Valerie, Zuck, Meghan, Bouchlaka, Myriam, Lam, Sam, Fox, Raymond, Whitman, Darbie, Graddis, Tom, Puri, Kamal D.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Abstract 1638: Discovery and preclinical characterization of anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

    Abstract 1638: Discovery and preclinical characterization of anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression by Bouchlaka, Myriam, Dinh, Huyen, Lam, Sam, Wall, Valerie, Whitman, Darbie, Chandrasekaran, Ramya, Harshman, Johanna, Loh, Texia, Loh, Lauren, Graddis, Tom, Puri, Kamal D., Probst, Peter

    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Abstract 6376: Discovery and preclinical characterization of dual antagonist antibodies targeting both LILRB1 and LILRB2 that enhance innate and adaptive anti-cancer immune responses

    Abstract 6376: Discovery and preclinical characterization of dual antagonist antibodies targeting both LILRB1 and LILRB2 that enhance innate and adaptive anti-cancer immune respons... by Zuck, Meghan, Bouchlaka, Myriam, Dinh, Huyen, Green, Kevin, Zapata, Francisco, Chandrasekaran, Ramya, Pisarenko, Tatyana, Loh, Lauren, Naika, Gajendra S., Sylvestre, Meilyn, Heit, Jacob, Fox, Raymond, Whitman, Darbie, Graddis, Tom, Puri, Kamal D., Probst, Peter

    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Designing Homodimers and Heterodimers with Sequence Simplified Leucine Zipper Models

    Designing Homodimers and Heterodimers with Sequence Simplified Leucine Zipper Models by Graddis, Tom, Chaiken, Irwin

    Request full text
    Report
    Save to List
    Saved in:

Search Tools: